FN2 Earnings Intelligence

Illumina, Inc. earnings overview

Latest Illumina, Inc. (ILMN) earnings intelligence, including the newest scorecard, market reaction, and transcript analysis.

Next reportIllumina, Inc. reports Thursday, Feb 4, 2027 · After market closeConsensus EPS $1.50 · consensus revenue $1.22B
ILMN FY2026 Q3 · Calendar Q4 2026

Illumina, Inc.

The supplied analysis supports a constructive operating trajectory: clinical sequencing demand, NovaSeq X placements and raised FY2026 guidance offset weaker research consumables. The longer-term contribution from BioInsight and the Billion Cell Atlas remains less established, while pricing, China and supply-chain risks could temper execution.

EPS surprise+19.1%
Market move-16.8%

Get the ILMN recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.